



Division of Medical Services Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



ARKANSAS MEDICAID DUR/DRC BOARD QUARTERLY DRUG UPDATE

October 18, 2023 8:30 A.M. – 12:30 P.M.

VIRTUAL ZOOM MEETING LINK

<https://us02web.zoom.us/j/85458850530?pwd=ZzdiZjg5REtaNVR3L1Z0OFJHNS80dz09>

Passcode: 052709

Or One tap mobile :

+13126266799,,85458850530# US (Chicago)

+14702509358,,85458850530# US (Atlanta)

Or Telephone:

Dial(for higher quality, dial a number based on your current location):

+1 312 626 6799 US (Chicago)

+1 470 250 9358 US (Atlanta)

+1 346 248 7799 US (Houston)

+1 602 753 0140 US (Phoenix)

+1 720 928 9299 US (Denver)

Webinar ID: 854 5885 0530

****TENTATIVE AGENDA IS SUBJECT TO CHANGE****

I. OUTSIDE SPEAKERS

DUR/DRC Board Bylaws, Section 7.02 Outside Speakers -- Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming DUR/DRC Board meeting agenda may request to speak on that product or topic. Requests to speak at the DUR/DRC Board meeting must be made in writing to the DUR Chairperson at least two (2) weeks before the DUR/DRC Board meeting date, and should include:

1. The speaker's name, title, relevant credentials, and organization;
2. Contact information for the speaker including address, telephone number, and email;
3. The agenda item(s) which the speaker intends to address;
4. Prepared comments; and
5. Any educational materials for Board members in advance of the meeting.

This information shall be included in information sent to Board members two (2) weeks prior to the Board meeting. Presentations or public comments given at the DUR/DRC Board meeting are limited to a total of six (6) minutes per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DUR/DRC Board members during the course of the meeting.

A copy of the proposed criteria for the specific agenda item on which an individual requests to speak may be requested from the Chairperson three (3) weeks prior to the DUR/DRC Board meeting. The information will be in draft form and may be changed by the DUR/DRC Board prior to being finalized. As such, the draft criteria should not be shared with clinicians or patients.

II. UNFINISHED / OLD BUSINESS AND GENERAL ORDERS / AND PROPOSALS TO REVISE PREVIOUS CRITERIA

A. ANNOUNCEMENTS

- 1) RESPIRATORY SYNCYTIAL VIRUS (RSV)
- 2) DIABETIC SUPPLIES UPDATE

B. APPROVAL OF THE MINUTES FROM THE PREVIOUS MEETING.

C. UPDATE ON SYSTEM EDITS, IMPLEMENTATIONS, OR FOLLOW-UP ITEMS.

- 1) Follow-up items from July 19, 2023 DUR/DRC Board: None
- 2) Implementation information from July 19, 2023 DUR/DRC Board

<https://humanservices.arkansas.gov/>

Protecting the vulnerable, fostering independence and promoting better health



**Division of Medical Services
Pharmacy Program**

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



- D. GENERAL INFORMATION
- E. PDL CLASS REVIEW WITHOUT CRITERIA (see specific medications on page 3)
 - 1) COLONY STIMULATING FACTORS
- F. PDL CLASS REVIEW WITH CRITERIA (see specific medications on page 3)
 - 1) MOVEMENT DISORDERS
 - 2) LONG-ACTING OPIOIDS
 - 3) LIPOTROPICS
- G. PROPOSED CHANGES TO EXISTING CRITERIA and EDITS, INCLUDING POINT OF SALE (POS) CRITERIA, MANUAL REVIEW PA CRITERIA, OR CLAIM EDITS: None

III. NEW BUSINESS

- A. PROPOSED NEW CLINICAL POINT OF SALE CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
- B. MANUAL REVIEW PROPOSED CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
 - 1) SKYCLARYS™ (omaveloxolone) capsule
 - 2) OLPRUVA™ (sodium phenylbutyrate) for oral suspension
 - 3) IMCIVREE® (setmelanotide) solution
 - 4) VANFLYTA® (quizartinib) tablet
 - 5) AKEEGA™ (niraparib tosylate monohydrate and abiraterone acetate) tablet
 - 6) VYJUVEK™ (beremagene geperpavec-svdt) gel
 - 7) TARGETED IMMUNOMODULATOR CRITERIA FOR GOUT FLARES
 - 8) SOHONOS™ (palovarotene) capsule
- C. PROPOSED NEW CLAIM EDITS (QUANTITY, DAILY DOSE, ACCUMULATION, GENDER, AGE): None
- D. ProDUR REPORT UPDATE
- E. RDUR REPORT UPDATE



PDL THERAPEUTIC CLASSES UNDER REVIEW

Colony Stimulating Factors: Fulphila® syringe, Fylnetra® syringe, Granix® syringe, Granix® vial, Leukine®, Neulasta® Onpro, Neulasta® syringe, Neupogen® syringe, Neupogen® vial, Nivestym® syringe, Nivestym® vial, Nyvepria™ syringe, Releuko® syringe, Releuko® vial, Rolvedon™ syringe, Stimufend® syringe, Udenyca® syringe, Udenyca® autoinjector, Zarxio® syringe, Ziextenzo® syringe

Movement disorders: Austedo®, Austedo® XR, Ingrezza®, tetrabenazine, Xenazine®

Long-Acting Opioids: Belbuca® film, buprenorphine patch, Butrans® patch, Conzip® capsule, fentanyl patch, hydrocodone ER capsule, hydrocodone ER tablet, hydromorphone ER tablet, Hysingla® ER tablet, methadone tablet, methadone concentrate, methadone solution, morphine ER capsule, morphine ER tablet, MS Contin® tablet, Nucynta ER® tablet, oxycodone ER tablet, Oxycontin® tablet, oxymorphone ER tablet, tramadol ER capsule, tramadol ER tablet (generic for Ryzolt®), tramadol ER (generic for Ultram ER®), Xtampza ER® capsule

Lipotropics: Antara® capsule, cholestyramine powder, colestevlam tablet (generic for Welchol®), Colestid® granules, Colestid® packet, Colestid® tablet, ezetimibe tablet (generic for Zetia®), fenofibrate 150 mg capsule (generic for Lipofen®), fenofibrate 30 mg, 90 mg, 130 mg capsule (generic for Antara®), fenofibrate 40 mg, 120 mg tablet (generic for Fenoglide®), fenofibrate 48 mg, 145 mg tablet (generic for Tricor®), fenofibrate 54 mg, 160 mg tablet (generic for Lofibra®), fenofibrate 67 mg, 134 mg, 200 mg capsule (generic for Tricor® or Lofibra®), fenofibric acid capsule (generic for Trilipix®), fenofibric acid tablet (generic for Fibricor®), Fenoglide® tablet, gemfibrozil tablet (generic for Lopid®), icosapent ethyl capsule (generic for Vascepa®), Juxtapid® capsule, Leqvio® injection, Lipofen® capsule, Lopid® tablet, Lovaza® capsule, Nexletol® tablet, Nexlizet® tablet, niacin ER tablet (generic for Niaspan®), niacin IR tablet, omega-3 acid ethyl ester capsule (generic for Lovaza®), Praluent® injection, Questran® powder, Repatha® injection, Tricor® tablet, Trilipix® capsule, Vascepa® capsule, Welchol® powder, Welchol® tablet, Zetia® tablet